

	n	Specimen Informa	ation	Client Information
		Specimen: Requisition:		
DOB:	AGE:	Lab Ref #:		
Gender:		Collected:		
Phone:		Received:		
Patient ID:		Reported:		
COMMENTS:	FASTING:YES			
Test Name	1715111(0.125	In Range	Out Of Range	Reference Range La
THYROID PANE THYROID PA		III Kalige	out of kange	
T3 UPTAK	E	32		22-35 %
	OXINE), TOTAL	9.2		4.9-10.5 mcg/dL
	INDEX (T7)	2.9 1.22		1.4-3.8 0.40-4.50 mIU/L
TSH LIPID PANEL,	STANDARD	1.22		0.40-4.50 mt0/1
CHOLESTERO			229 Н	<200 mg/dL
HDL CHOLES		66		>40 mg/dL
TRIGLYCERI LDL-CHOLES		77	145 H	<150 mg/dL mg/dL (calc)
	nce range: <100		145 H	mg/dL (Cale)
estima [.] Martin	OLESTEROL	013;310(19): 206 iagnostics.com/f 3.5	1-2068 aq/FAQ164) 163 H	<5.0 (calc) <130 mg/dL (calc)
factor (LDL-C option COMPREHENSIV		n-HDL-C goal of	<100 mg/dL	
factor (LDL-C option	, treating to a no of <70 mg/dL) is	n-HDL-C goal of	<100 mg/dL	65-99 mg/dL
factor (LDL-C option COMPREHENSIV PANEL	, treating to a no of <70 mg/dL) is	n-HDL-C goal of	<100 mg/dL prapeutic 111 H	65-99 mg/dL sting reference interval
factor (LDL-C option COMPREHENSIV PANEL GLUCOSE For som between predial	, treating to a no of <70 mg/dL) is	n-HDL-C goal of considered a the n diabetes, a gl L is consistent	<100 mg/dL erapeutic 111 H Fa ucose value with	-
factor (LDL-C option COMPREHENSIV PANEL GLUCOSE For som between predial follow UREA NITRO	, treating to a no of <70 mg/dL) is	n-HDL-C goal of considered a the n diabetes, a gl L is consistent e confirmed with 16	<100 mg/dL erapeutic 111 H Fa ucose value with	sting reference interval 7-25 mg/dL
factor (LDL-C option COMPREHENSIV PANEL GLUCOSE For son between predial follow UREA NITRO CREATININE For pa for Creating	, treating to a no of <70 mg/dL) is	n-HDL-C goal of considered a the n diabetes, a gl L is consistent e confirmed with 16 0.77 f age, the refer cimately 13% high	<100 mg/dL erapeutic 111 H Fa ucose value with a ence limit	sting reference interval
factor (LDL-C option COMPREHENSIV PANEL GLUCOSE For som between predial follow UREA NITRO CREATININE For pai for Creation	, treating to a no of <70 mg/dL) is	n-HDL-C goal of considered a the n diabetes, a gl L is consistent e confirmed with 16 0.77 f age, the refer cimately 13% high	<100 mg/dL erapeutic 111 H Fa ucose value with a ence limit	sting reference interval 7-25 mg/dL 0.70-1.33 mg/dL
factor (LDL-C option COMPREHENSIV PANEL GLUCOSE For som between predial follow UREA NITRO CREATININE For par for Cra identi:	, treating to a no of <70 mg/dL) is	n-HDL-C goal of considered a the n diabetes, a gl L is consistent e confirmed with 16 0.77 f age, the refer imately 13% high erican. 106 123	<100 mg/dL erapeutic 111 H Fa ucose value with a ence limit er for people	<pre>sting reference interval 7-25 mg/dL 0.70-1.33 mg/dL > OR = 60 mL/min/1.73m2 > OR = 60 mL/min/1.73m2</pre>
factor (LDL-C option COMPREHENSIV PANEL GLUCOSE For son between predial follow UREA NITRO CREATININE For par for Cra identi: eGFR NON-A eGFR AFRIC BUN/CREATI	, treating to a no of <70 mg/dL) is	n-HDL-C goal of considered a the n diabetes, a gl L is consistent e confirmed with 16 0.77 f age, the refer imately 13% high erican. 106 123 NOT APPLIC.	<100 mg/dL erapeutic 111 H Fa ucose value with a ence limit er for people	<pre>sting reference interval 7-25 mg/dL 0.70-1.33 mg/dL > OR = 60 mL/min/1.73m2 > OR = 60 mL/min/1.73m2 6-22 (calc)</pre>
factor (LDL-C option COMPREHENSIV PANEL GLUCOSE For som between predial follow UREA NITRO CREATININE For par for Creation identic	, treating to a no of <70 mg/dL) is	n-HDL-C goal of considered a the n diabetes, a gl L is consistent e confirmed with 16 0.77 f age, the refer imately 13% high erican. 106 123	<100 mg/dL erapeutic 111 H Fa ucose value with a ence limit er for people	<pre>sting reference interval 7-25 mg/dL 0.70-1.33 mg/dL > OR = 60 mL/min/1.73m2 > OR = 60 mL/min/1.73m2</pre>

CLIENT SERVICES: 866.697.8378

SPECIMEN:



Detion tuformation	Succision Information	Client Information
Patient Information	Specimen Information	
	Specimen:	
	Collected:	
DOB: AGE:	Received:	
Gender:	Reported:	
Patient ID:		
Test Name	In Range Out Of Range	Reference Range Lab
CARBON DIOXIDE	19 L	20-32 mmol/L
CALCIUM	10.3	8.6-10.3 mg/dL
PROTEIN, TOTAL ALBUMIN	7.1 4.9	6.1-8.1 g/dL 3.6-5.1 g/dL
GLOBULIN	2.2	1.9-3.7 g/dL (calc)
ALBUMIN/GLOBULIN RATIO	2.2	1.0-2.5 (calc)
BILIRUBIN, TOTAL	1.2	0.2-1.2 mg/dL
ALKALINE PHOSPHATASE	57 25	40-115 U/L
AST ALT	25	10-35 U/L 9-46 U/L
HEMOGLOBIN A1c	5.5	<5.7 % of total Hgb
For the purpose of screenin	g for the presence of	J
diabetes:		
<5.7% Consistent with	the absence of diabetes	
	increased risk for diabetes	
(prediabetes) > or =6.5% Consistent with	diabetes	
This assay result is consis of diabetes.	tent with a decreased risk	
Currently, no consensus exi hemoglobin Alc for diagnosi		
According to American Diabe guidelines, hemoglobin Alc control in non-pregnant dia metrics may apply to specif Standards of Medical Care i	<7.0% represents optimal betic patients. Different ic patient populations.	
PHOSPHATE (AS PHOSPHORUS)	3.7	2.5-4.5 mg/dL
URIC ACID	5.9	4.0-8.0 mg/dL
Therapeutic target for gout	patients: <6.0 mg/dL	
LD	229	120-250 U/L
GGT	20	3-95 U/L
CBC (INCLUDES DIFF/PLT)		
WHITE BLOOD CELL COUNT	4.2	3.8-10.8 Thousand/uL
RED BLOOD CELL COUNT HEMOGLOBIN	4.97 15.3	4.20-5.80 Million/uL 13.2-17.1 g/dL
HEMATOCRIT	45.5	38.5-50.0 %
MCV	91.5	80.0-100.0 fL
MCH	30.8	27.0-33.0 pg
MCHC	33.6	32.0-36.0 g/dL
RDW PLATELET COUNT	11.9 217	11.0-15.0 % 140-400 Thousand/uL
MPV	11.4	7.5-12.5 fL
ABSOLUTE NEUTROPHILS	2654	1500-7800 cells/uL
ABSOLUTE LYMPHOCYTES	1142	850-3900 cells/uL
ABSOLUTE MONOCYTES ABSOLUTE EOSINOPHILS	244 130	200-950 cells/uL 15-500 cells/uL
ABSOLUTE BASOPHILS	29	0-200 cells/uL
NEUTROPHILS	63.2	8
LYMPHOCYTES	27.2	8
MONOCYTES	5.8	8

SPECIMEN:



Patient Information		Specimen Informa	Specimen Information		Client Information	
		Specimen:				
		Collected:				
DOB:	AGE:	Received:				
Gender:		Reported:				
Patient ID:						
Test Name	e	In Range	Out Of Range	Reference Range	Lab	
EOSINOF	PHILS	3.1		ę		
BASOPHI	ILS	0.7		80		
IRON, TOT	TAL	137		50-180 mcg/dL		
INSULIN		3.6		2.0-19.6 uIU/mL		
som and	e insulin analogs	shows strong cross-re s (lispro, aspart, and s-reactivity with oth	d glargine)			

PERFORMING SITE:

CLIENT SERVICES: 866.697.8378